Literature DB >> 8211180

Germ-line gene modification and disease prevention: some medical and ethical perspectives.

N A Wivel1, L Walters.   

Abstract

There has been considerable debate about the ethics of human germ-line gene modification. As a result of recent advances in the micromanipulation of embryos and the laboratory development of transgenic mice, a lively discussion has begun concerning both the technical feasibility and the ethical acceptability of human germ-line modification for the prevention of serious disease. This article summarizes some of the recent research on germ-line gene modification in animal models. Certain monogenic deficiency diseases that ultimately might be candidates for correction by germ-line intervention are identified. Several of the most frequently considered ethical issues relative to human germ-line gene modification are considered in the context of professional ethics, parental responsibility, and public policy. Finally, it is suggested that there is merit in continuing the discussion about human germ-line intervention, so that this technique can be carefully compared with alternative strategies for preventing genetic disease.

Entities:  

Keywords:  Analytical Approach; Genetics and Reproduction

Mesh:

Year:  1993        PMID: 8211180     DOI: 10.1126/science.8211180

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  10 in total

Review 1.  Current aspects of gene therapy: implications for vascular interventions.

Authors:  F Reifers; J Kreuzer
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

2.  Ethics and germline gene editing.

Authors:  Jeremy Sugarman
Journal:  EMBO Rep       Date:  2015-07-02       Impact factor: 8.807

3.  Spermatogonial stem cells of the testis.

Authors:  M Dym
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

4.  Responsible innovation in human germline gene editing: Background document to the recommendations of ESHG and ESHRE.

Authors:  Guido De Wert; Björn Heindryckx; Guido Pennings; Angus Clarke; Ursula Eichenlaub-Ritter; Carla G van El; Francesca Forzano; Mariëtte Goddijn; Heidi C Howard; Dragica Radojkovic; Emmanuelle Rial-Sebbag; Wybo Dondorp; Basil C Tarlatzis; Martina C Cornel
Journal:  Eur J Hum Genet       Date:  2018-01-12       Impact factor: 4.246

5.  Fostering a prevention mindset for responsible gene editing.

Authors:  Karen M Meagher; Zubin Master
Journal:  Account Res       Date:  2019-05-17       Impact factor: 2.622

Review 6.  Cytokine-modulating strategies and newer cytokine targets for arthritis therapy.

Authors:  Shivaprasad H Venkatesha; Steven Dudics; Bodhraj Acharya; Kamal D Moudgil
Journal:  Int J Mol Sci       Date:  2014-12-31       Impact factor: 5.923

7.  Human Germline Interventions-Think First.

Authors:  Elisabeth Hildt
Journal:  Front Genet       Date:  2016-05-09       Impact factor: 4.599

8.  Nanomedicine: techniques, potentials, and ethical implications.

Authors:  Mette Ebbesen; Thomas G Jensen
Journal:  J Biomed Biotechnol       Date:  2006

Review 9.  Transgeneration carcinogenesis: a review of the experimental and epidemiological evidence.

Authors:  L Tomatis
Journal:  Jpn J Cancer Res       Date:  1994-05

10.  Responsible innovation in human germline gene editing. Background document to the recommendations of ESHG and ESHRE.

Authors:  Guido de Wert; Björn Heindryckx; Guido Pennings; Angus Clarke; Ursula Eichenlaub-Ritter; Carla G van El; Francesca Forzano; Mariëtte Goddijn; Heidi C Howard; Dragica Radojkovic; Emmanuelle Rial-Sebbag; Wybo Dondorp; Basil C Tarlatzis; Martina C Cornel
Journal:  Hum Reprod Open       Date:  2018-01-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.